Skip to main content
Erschienen in: Journal of Genetic Counseling 1/2016

01.02.2016 | Original Research

Attitudes and Knowledge of Maternal-Fetal Medicine Fellows Regarding Noninvasive Prenatal Testing

verfasst von: Paul Swaney, Emily Hardisty, Lauren Sayres, Samantha Wiegand, Neeta Vora

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Using cell-free DNA in maternal serum to detect fetal aneuploidy has been shown to have high sensitivity and specificity. The purpose of this study was to assess attitudes and knowledge of Maternal-Fetal Medicine (MFM) fellows regarding noninvasive prenatal testing (NIPT). A 13 question survey was sent via listserv to US-based MFM fellows. One hundred sixteen fellows responded, a 42.3 % response rate, with >75 % reporting they are comfortable ordering NIPT. Most (82 %) preferred that a patient discuss options with a provider or genetic counselor. Three common methods used to learn about NIPT were: formal educational activities (n = 78, 69 %), self-review of the literature (n = 76, 67 %), and discussions with peers (n = 73, 65 %). On questions related to trisomy 21, accuracy was >70 %. However, accuracy was lower regarding use in twin pregnancies (42 %) and monosomy X screening (50 %).
Literatur
Zurück zum Zitat American College of Obstetricians and Gynecologists Committee on Genetics. Committee opinion no. 545. (2012). Noninvasive prenatal testing for fetal aneuploidy. Obstetrics and Gynecology, 120(6), 1532–1534.CrossRef American College of Obstetricians and Gynecologists Committee on Genetics. Committee opinion no. 545. (2012). Noninvasive prenatal testing for fetal aneuploidy. Obstetrics and Gynecology, 120(6), 1532–1534.CrossRef
Zurück zum Zitat Benn, P. A., & Chapman, A. R. (2010). Ethical challenges in providing noninvasive prenatal diagnosis. Current Opinion in Obstetrics and Gynecology, 22(2), 128–134.CrossRefPubMed Benn, P. A., & Chapman, A. R. (2010). Ethical challenges in providing noninvasive prenatal diagnosis. Current Opinion in Obstetrics and Gynecology, 22(2), 128–134.CrossRefPubMed
Zurück zum Zitat Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., Rava, R. P., et al. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstetrics and Gynecology, 119(5), 890–901.CrossRefPubMed Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., Rava, R. P., et al. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstetrics and Gynecology, 119(5), 890–901.CrossRefPubMed
Zurück zum Zitat Bianchi, D. W., Prosen, T., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Rava, R. P., et al. (2013). Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma. Obstetrics and Gynecology, 121(5), 1057–1062.CrossRefPubMed Bianchi, D. W., Prosen, T., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Rava, R. P., et al. (2013). Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma. Obstetrics and Gynecology, 121(5), 1057–1062.CrossRefPubMed
Zurück zum Zitat Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., et al. (2014). DNA sequencing versus standard prenatal aneuploidy screening. New England Journal of Medicine, 370(9), 799–808.CrossRefPubMed Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., et al. (2014). DNA sequencing versus standard prenatal aneuploidy screening. New England Journal of Medicine, 370(9), 799–808.CrossRefPubMed
Zurück zum Zitat Brierley, K. L., Blouch, E., Cogswell, W., Homer, J. P., Pencarinha, D., Stanislaw, C. L., et al. (2012). Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer Journal, 18(4), 303–309.CrossRef Brierley, K. L., Blouch, E., Cogswell, W., Homer, J. P., Pencarinha, D., Stanislaw, C. L., et al. (2012). Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer Journal, 18(4), 303–309.CrossRef
Zurück zum Zitat Madan, K., & Breuning, M. H. (2014). Impact of prenatal technologies on the sex ratio in India: an overview. Genetics in Medicine, 16(6), 425–32.PubMedCentralCrossRefPubMed Madan, K., & Breuning, M. H. (2014). Impact of prenatal technologies on the sex ratio in India: an overview. Genetics in Medicine, 16(6), 425–32.PubMedCentralCrossRefPubMed
Zurück zum Zitat Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., et al. (2011). DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genetics in Medicine, 13(11), 913–920.CrossRefPubMed Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., et al. (2011). DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genetics in Medicine, 13(11), 913–920.CrossRefPubMed
Zurück zum Zitat Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A., Weinberg, A. D., et al. (2011). Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genetics in Medicine, 13(2), 148–154.PubMedCentralCrossRefPubMed Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A., Weinberg, A. D., et al. (2011). Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genetics in Medicine, 13(2), 148–154.PubMedCentralCrossRefPubMed
Zurück zum Zitat Sayres, L. C., Allyse, M., Norton, M. E., & Cho, M. K. (2011). Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenatal Diagnosis, 31(11), 1070–1076.PubMedCentralCrossRefPubMed Sayres, L. C., Allyse, M., Norton, M. E., & Cho, M. K. (2011). Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenatal Diagnosis, 31(11), 1070–1076.PubMedCentralCrossRefPubMed
Zurück zum Zitat Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225.CrossRefPubMed Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225.CrossRefPubMed
Zurück zum Zitat Vora, N. L., & O’Brien, B. M. (2014). Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: Proceed with caution. Obstetrics and Gynecology, 123(5), 1097–1099.CrossRefPubMed Vora, N. L., & O’Brien, B. M. (2014). Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: Proceed with caution. Obstetrics and Gynecology, 123(5), 1097–1099.CrossRefPubMed
Zurück zum Zitat Wapner RJ, Babiarz JE, Levy B, et al. (2015) Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. American journal of obstetrics and gynecology, 212(3): 332.e1-9 Wapner RJ, Babiarz JE, Levy B, et al. (2015) Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. American journal of obstetrics and gynecology, 212(3): 332.e1-9
Zurück zum Zitat You, Y., Sun, Y., Li, X., Li, Y., Wei, X., Chen, F., et al. (2013). Integration of targeted sequencing and NIPT into clinical practice in a Chinese family with maple syrup urine disease. Genetics in Medicine, 16, 594–600.CrossRef You, Y., Sun, Y., Li, X., Li, Y., Wei, X., Chen, F., et al. (2013). Integration of targeted sequencing and NIPT into clinical practice in a Chinese family with maple syrup urine disease. Genetics in Medicine, 16, 594–600.CrossRef
Metadaten
Titel
Attitudes and Knowledge of Maternal-Fetal Medicine Fellows Regarding Noninvasive Prenatal Testing
verfasst von
Paul Swaney
Emily Hardisty
Lauren Sayres
Samantha Wiegand
Neeta Vora
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 1/2016
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-015-9844-6

Weitere Artikel der Ausgabe 1/2016

Journal of Genetic Counseling 1/2016 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.